Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2017-02-23 Annual Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Annual Report 2016
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Genmab A/S for the fiscal year 2016. It includes a table of contents, a shareholder letter, detailed management reviews, financial statements, and an independent auditor's report. It is clearly the full annual report rather than an announcement or a summary. FY 2016
2017-02-23 English
Genmab 2016 Annual Report
Report Publication Announcement Classification · 85% confidence The document is a press release titled “Company Announcement” stating that Genmab A/S has published its Annual Report for 2016, provides a high‐level summary of business progress and financial performance, and notes that the full report is attached as a PDF or available on the website. It does not include the complete financial statements itself but serves to announce the publication of the full Annual Report. Under the “menu vs. meal” rule, this is a report publication announcement rather than the report itself.
2017-02-22 English
Genmab 2016 Annual Report
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2016' and contains comprehensive sections including a shareholder letter, management's review, detailed product pipeline information, corporate governance, and financial statements for the Genmab Group. It meets the criteria for an Annual Report (10-K) as it covers company activity and full financial performance for the fiscal year. FY 2016
2017-02-22 English
Genmab 2016 Annual Report
Report Publication Announcement Classification · 94% confidence The document is a company announcement summarizing the 2016 Annual Report with highlights of business achievements, financial performance, and 2017 outlook, and explicitly states that the full report is attached as a PDF and available on the website. It does not contain the full annual report itself but serves to announce its publication. Under the “menu vs meal” rule, this qualifies as a Report Publication Announcement.
2017-02-22 English
Share Issue/Capital Change 2017
Share Issue/Capital Change Classification · 99% confidence The document is titled "Company Announcement" and details the grant of restricted stock units and warrants to employees. This type of announcement relates to executive/employee compensation and equity structure changes. While it touches upon remuneration (DEF 14A) and capital structure (CAP/SHA), the core subject is the issuance of equity instruments (RSUs and Warrants) to employees as part of an incentive plan. This is most closely aligned with announcements regarding capital structure changes or share transactions, but given the context of executive/employee incentives, it often falls under general corporate actions. Since the document explicitly details the grant of stock units and warrants, which are forms of share issuance/capital structure modification, and it is not a formal regulatory filing like a 10-K or a general earnings release, the closest fit among the provided specific codes is 'Share Issue/Capital Change' (SHA) or potentially 'Transaction in Own Shares' (POS) if the shares are being repurchased for issuance, or 'Remuneration Information' (DEF 14A). However, the text focuses on the *grant* and *terms* of the equity instruments themselves rather than just the compensation disclosure required in a DEF 14A. Since warrants and RSUs are direct capital instruments, SHA is a strong candidate. Alternatively, since this is a specific corporate action announcement that doesn't fit perfectly into the main financial reports, it could be RNS. Given the nature of granting equity awards, SHA (Share Issue/Capital Change) is the most specific fit for the mechanics described, although RNS is a possibility if it's viewed as a general corporate update. I will classify it as SHA because it directly concerns the issuance of shares via RSUs and warrants, which alters the capital structure. If SHA is too broad, RNS is the fallback. Considering the specific nature of the grant, SHA is preferred over the general RNS.
2017-02-10 English
Share Issue/Capital Change 2017
Share Issue/Capital Change Classification · 99% confidence The document is titled "Company Announcement" and details the decision by the board to grant restricted stock units (RSUs) and warrants to employees. This action directly relates to the company's compensation structure and the issuance of equity instruments to personnel. This falls under the scope of capital structure changes or remuneration/incentive plans. Reviewing the definitions, the closest fit is 'Share Issue/Capital Change' (SHA) as it involves the issuance of shares via RSUs and warrants, or potentially 'Remuneration Information' (DEF 14A) if it were a full proxy statement on compensation. However, the core action is the grant of equity awards (shares/options). Since it is a specific announcement about granting equity instruments (RSUs and Warrants) to employees, which affects the capital structure, 'SHA' (Share Issue/Capital Change) is a strong candidate. Alternatively, since it is an announcement about employee incentives, it could be related to compensation, but 'DEF 14A' is specifically for remuneration reports/proxy statements. Given the direct mention of granting shares/rights to shares, 'SHA' is the most precise fit among the provided options for an announcement detailing the mechanics of an equity grant to employees. It is not a general regulatory filing (RNS) because it fits a specific category.
2017-02-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.